Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
BF Haynes, K Wiehe, P Borrow, KO Saunders… - Nature Reviews …, 2023 - nature.com
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure
PD Kwong, JR Mascola - Immunity, 2018 - cell.com
HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …
Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies
WB Williams, RR Meyerhoff, RJ Edwards, H Li… - Cell, 2021 - cell.com
Natural antibodies (Abs) can target host glycans on the surface of pathogens. We studied
the evolution of glycan-reactive B cells of rhesus macaques and humans using glycosylated …
the evolution of glycan-reactive B cells of rhesus macaques and humans using glycosylated …
Targeted selection of HIV-specific antibody mutations by engineering B cell maturation
INTRODUCTION A major goal of HIV-1 vaccine development is the design of immunogens
that induce broadly neutralizing antibodies (bnAbs). However, vaccination of humans has …
that induce broadly neutralizing antibodies (bnAbs). However, vaccination of humans has …
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
The development of an effective AIDS vaccine remains a challenge. Nucleoside-modified
mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of …
mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of …
Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions
Targeting germline (gl-) precursors of broadly neutralizing antibodies (bNAbs) is
acknowledged as an important strategy for HIV-1 vaccines. The VRC01-class of bNAbs is …
acknowledged as an important strategy for HIV-1 vaccines. The VRC01-class of bNAbs is …
Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global
viruses, are a major focus of HIV vaccine design, with data from animal studies confirming …
viruses, are a major focus of HIV vaccine design, with data from animal studies confirming …
Immunogenicity of RNA replicons encoding HIV Env immunogens designed for self-assembly into nanoparticles
RNA replicons are a promising platform technology for vaccines. To evaluate the potential of
lipid nanoparticle-formulated replicons for delivery of HIV immunogens, we designed and …
lipid nanoparticle-formulated replicons for delivery of HIV immunogens, we designed and …
Vaccine induction of heterologous tier 2 HIV-1 neutralizing antibodies in animal models
KO Saunders, LK Verkoczy, C Jiang, J Zhang, R Parks… - Cell reports, 2017 - cell.com
The events required for the induction of broad neutralizing antibodies (bnAbs) following HIV-
1 envelope (Env) vaccination are unknown, and their induction in animal models as proof of …
1 envelope (Env) vaccination are unknown, and their induction in animal models as proof of …